egfr mutation resulting in tyrosine kinase inhibitor resistance
Showing 1 - 3 of 3
Lung Tumor Malignant, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-451)
Recruiting
- Lung Neoplasm Malignant
- +18 more
-
Fairfax, VirginiaNew Experimental Therapeutics of Virginia (NEXT Oncology)
Mar 29, 2022